Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

Ataraxis AI 获得 2040 万美元 A 轮融资，推动癌症治疗中的精准医疗变革

With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market

在AIX Ventures、彼得·蒂尔以及医疗保健和人工智能先锋的新支持下，Ataraxis AI 有望迅速将其首款产品 Atarasis Breast 推向市场。

NEW YORK, March 5, 2025-- Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures.

纽约，2025年3月5日——领先的AI精准医疗公司Ataraxis AI今天宣布完成了2040万美元的A轮融资，本轮融资由AIX Ventures领投，Floating Point、Thiel Bio、Founders Fund、Bertelsmann Investments以及现有投资者Giant Ventures和Obvious Ventures参与。

The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMind also participated..

本轮融资还得到了天使投资人和医疗保健领域先驱的支持，包括奥斯卡健康（Oscar Health，纽约证券交易所代码：OSCR）的联合创始人兼前首席执行官马里奥·施洛瑟（Mario Schlosser）、Tempus的首席运营官瑞安·福库山（Ryan Fukushima）等人。来自OpenAI和DeepMind的领先研究人员也参与其中。

Founded by Jan Witowski, MD, PhD, and Krzysztof Geras, PhD, Ataraxis AI is reshaping cancer diagnostics with a frontier AI foundation model called Kestrel. The capital infusion comes as the company’s first offering, Ataraxis Breast—the world’s first AI-native prognostic/predictive platform for breast cancer—was clinically validated in a landmark study to be 30 percent more accurate than the current standard of care for breast cancer.

由扬·维托夫斯基（Jan Witowski）医学博士、哲学博士和克里斯托夫·格拉西克（Krzysztof Geras）哲学博士创立的Ataraxis AI，正在通过一款名为“隼”（Kestrel）的前沿人工智能基础模型重塑癌症诊断。此次资金注入之际，该公司的首款产品——Ataraxis Breast（全球首个用于乳腺癌的原生人工智能预后/预测平台）——在一项具有里程碑意义的研究中得到临床验证，其准确性比目前乳腺癌的标准护理高出30%。

Ataraxis AI is on track to launch Ataraxis Breast for clinical use later this year for oncologists across the United States. This new financing will also support the continuing development of offerings by expanding treatment selection capabilities within and beyond breast cancer as well as the development of next-generation AI foundation models..

Ataraxis AI 计划在今年晚些时候推出 Ataraxis Breast，供美国各地的肿瘤学家临床使用。这一新的融资还将支持通过扩展乳腺癌内外的治疗选择能力，以及开发下一代人工智能基础模型，来持续推进产品的发展。

“This investment is a testament to the groundbreaking work our team is accomplishing and the immense potential of AI in precision medicine. It also reflects our progress, securing funding just a few months after receiving clinical validation,” said Jan Witowski, MD, PhD, co-founder and CEO, Ataraxis AI.

“这项投资证明了我们团队正在取得的开创性工作以及人工智能在精准医疗领域的巨大潜力。这也反映了我们的进展，即在获得临床验证后的几个月内就获得了资金支持，”Ataraxis AI联合创始人兼首席执行官Jan Witowski医学博士表示。

“With this capital, we are on track to further accelerate our mission to change how cancer is treated and ultimately impact at least 50 percent of new cancer cases by 2030.”.

“有了这笔资金，我们将进一步加速实现改变癌症治疗方式的使命，并最终在2030年前影响至少50%的新发癌症病例。”

Through novel optimization strategies and methodological sophistication, Kestrel beats existing state-of-the-art models with less required data and computational power. The model outperforms existing approaches by uncovering complex, previously undetectable patterns linked to patient outcomes across all disease types.

通过新颖的优化策略和方法学的精进，Kestrel在所需数据和计算能力更少的情况下超越了现有的最先进模型。该模型通过揭示与所有疾病类型中患者结果相关的复杂且此前无法检测到的模式，超越了现有方法。

Kestrel is the first of Ataraxis’ foundation models, which will power the development of treatment selection tools for all cancer types..

Kestrel是Ataraxis首个基础模型，将为所有癌症类型治疗选择工具的开发提供支持。

Ataraxis AI also announced its Clinical Advisory Board, which boasts an impressive roster of medical oncology key opinion leaders from top health systems, including: Dr. Francisco Esteva (Chief of Hematology and Medical Oncology at Northwell Lenox Hill), Dr. Lajos Pusztai (Co-Leader Genetics, Genomics and Epigenetics Program at Yale Cancer Center), Dr.

Ataraxis AI 还宣布了其临床顾问委员会，该委员会拥有来自顶级卫生系统的医学肿瘤学关键意见领袖的令人印象深刻的名单，包括：弗朗西斯科·埃斯特瓦博士（北岸列诺克斯山血液学和医学肿瘤学主任）、拉约什·普斯泰博士（耶鲁癌症中心遗传学、基因组学和表观遗传学项目联合负责人）。

Adam Brufsky (Co-Director of the Cancer Therapeutics Program at the UPMC Hillman Cancer Center), and Dr. Freya Schnabel (Director of Breast Surgery, NYU). These additions join Yann LeCun, PhD, Chief AI Scientist at Meta and Turing Award Laureate, who serves as the company’s AI advisor..

亚当·布鲁夫斯基（UPMC希尔曼癌症中心癌症治疗项目联合主任），弗雷娅·施纳贝尔博士（纽约大学乳腺手术主任）。他们与现任公司AI顾问的Meta首席AI科学家、图灵奖得主杨立昆博士一同加入。

“In the next five years, the world’s leading oncology centers won’t just have top physicians—they’ll have AI copilots revolutionizing diagnosis and treatment. Ataraxis AI is at the forefront of this transformation, and its breakthrough platform, Kestrel, is setting a new standard for precision oncology,” said Krish Ramadurai, Partner at AIX Ventures.

“在未来五年内，世界领先的肿瘤中心不仅会拥有最优秀的医生，还会有革新诊断和治疗的AI助手。Ataraxis AI处于这一变革的前沿，其突破性平台Kestrel正在为精准肿瘤学树立新标准，”AIX Ventures合伙人Krish Ramadurai表示。

“Jan and his team aren’t just building another AI tool—they’re redefining how cancer is detected and treated, with the potential to improve millions of lives. We couldn’t be more excited to back them on this journey.”.

“扬和他的团队不仅仅是在构建另一个AI工具——他们正在重新定义癌症的检测和治疗方法，有潜力改善数百万人的生活。我们非常兴奋能够在这段旅程中支持他们。”

About Ataraxis AI

关于Ataraxis AI

Ataraxis is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. Backed by leading investors AIX Ventures, Floating Point, Bertelsmann Investments, Thiel Bio, Founders Fund, Giant Ventures, and Obvious Ventures, the company is addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data.

Ataraxis是一家人工智能精准医疗公司，通过人工智能的力量改善患者预后。该公司得到了AIX Ventures、Floating Point、Bertelsmann Investments、Thiel Bio、Founders Fund、Giant Ventures和Obvious Ventures等领先投资者的支持，正在利用前沿的基础模型和多模态数据解决以往无法解决的癌症预后和治疗选择问题。

Ataraxis’ first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive platform for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai..

Ataraxis 的首个经过临床验证的产品 Ataraxis Breast 是全球首个针对乳腺癌的原生人工智能预后/预测平台，其准确性高于标准的基因组检测方法。欲了解更多信息，请访问 ataraxis.ai。

Contact:

联系人：

Media Contact

媒体联系人

Pluck for Ataraxis AI

为Ataraxis AI采摘

press@ataraxis.ai

press@ataraxis.ai